{"product_id":"global-biologics-and-biosimilars-market-growth-2023-2029","title":"Global Biologics and Biosimilars Market Growth 2023-2029","description":"\u003cp\u003eGlobal Biologics and Biosimilars Market Growth 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eA biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.\u003cbr\u003e\nA biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.\u003cbr\u003e\nLPI (LP Information)' newest research report, the “Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2023 through 2029. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics and Biosimilars industry.\u003cbr\u003e\nThis Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biologics and Biosimilars market.\u003cbr\u003e\nThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.\u003cbr\u003e\nThe global Biologics and Biosimilars market size is projected to grow from US$ 189000 million in 2022 to US$ 271130 million in 2029; it is expected to grow at a CAGR of 271130 from 2023 to 2029.\u003cbr\u003e\nThe major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson \u0026amp; Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.\u003cbr\u003e\nThis report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.\u003cbr\u003e\nMarket Segmentation:\u003cbr\u003e\nSegmentation by type\u003cbr\u003e\n Monoclonal Antibodies\u003cbr\u003e\n Interferon\u003cbr\u003e\n Erythropoietin\u003cbr\u003e\n Insulin\u003cbr\u003e\n Vaccines\u003cbr\u003e\n Others\u003cbr\u003e\nSegmentation by application\u003cbr\u003e\n Tumor\u003cbr\u003e\n Diabetes\u003cbr\u003e\n Cardiovascular\u003cbr\u003e\n Hemophilia\u003cbr\u003e\n Others\u003cbr\u003e\nThis report also splits the market by region:\u003cbr\u003e\n Americas\u003cbr\u003e\n United States\u003cbr\u003e\n Canada\u003cbr\u003e\n Mexico\u003cbr\u003e\n Brazil\u003cbr\u003e\n APAC\u003cbr\u003e\n China\u003cbr\u003e\n Japan\u003cbr\u003e\n Korea\u003cbr\u003e\n Southeast Asia\u003cbr\u003e\n India\u003cbr\u003e\n Australia\u003cbr\u003e\n Europe\u003cbr\u003e\n Germany\u003cbr\u003e\n France\u003cbr\u003e\n UK\u003cbr\u003e\n Italy\u003cbr\u003e\n Russia\u003cbr\u003e\n Middle East \u0026amp; Africa\u003cbr\u003e\n Egypt\u003cbr\u003e\n South Africa\u003cbr\u003e\n Israel\u003cbr\u003e\n Turkey\u003cbr\u003e\n GCC Countries\u003cbr\u003e\nThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\n Roche\u003cbr\u003e\n Amgen\u003cbr\u003e\n AbbVie\u003cbr\u003e\n Sanofi-Aventis\u003cbr\u003e\n Johnson \u0026amp; Johnson\u003cbr\u003e\n Pfizer\u003cbr\u003e\n Novo Nordisk\u003cbr\u003e\n Eli Lilly\u003cbr\u003e\n Novartis\u003cbr\u003e\n Merck\u003cbr\u003e\n 3sbio\u003cbr\u003e\n Changchun High Tech\u003cbr\u003e\n CP Guojian\u003cbr\u003e\n Biotech\u003cbr\u003e\n Gelgen\u003cbr\u003e\n Innovent\u003cbr\u003e\n Dong Bao\u003cbr\u003e\n Ganlee\u003cbr\u003e\n United Laboratories\u003cbr\u003e\nKey Questions Addressed in this Report\u003cbr\u003e\nWhat is the 10-year outlook for the global Biologics and Biosimilars market?\u003cbr\u003e\nWhat factors are driving Biologics and Biosimilars market growth, globally and by region?\u003cbr\u003e\nWhich technologies are poised for the fastest growth by market and region?\u003cbr\u003e\nHow do Biologics and Biosimilars market opportunities vary by end market size?\u003cbr\u003e\nHow does Biologics and Biosimilars break out type, application?\u003cbr\u003e\nWhat are the influences of COVID-19 and Russia-Ukraine war?\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 116 Pages \/ MCW16225896","offer_id":47640098963762,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-biologics-and-biosimilars-market-growth-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}